CN111187838B - A specific methylation marker related to benzo[a]pyrene contamination for lung cancer diagnosis and its screening method and use - Google Patents
A specific methylation marker related to benzo[a]pyrene contamination for lung cancer diagnosis and its screening method and use Download PDFInfo
- Publication number
- CN111187838B CN111187838B CN201911361331.7A CN201911361331A CN111187838B CN 111187838 B CN111187838 B CN 111187838B CN 201911361331 A CN201911361331 A CN 201911361331A CN 111187838 B CN111187838 B CN 111187838B
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- methylation
- benzo
- dna
- pyrene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000011987 methylation Effects 0.000 title claims abstract description 90
- 238000007069 methylation reaction Methods 0.000 title claims abstract description 90
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 77
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 76
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 76
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 239000003550 marker Substances 0.000 title claims abstract description 18
- 238000011109 contamination Methods 0.000 title claims description 5
- 238000003745 diagnosis Methods 0.000 title abstract description 28
- 238000000034 method Methods 0.000 title abstract description 12
- 238000012216 screening Methods 0.000 title abstract description 10
- 210000000349 chromosome Anatomy 0.000 claims abstract description 17
- 101150084398 PTAFR gene Proteins 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000007067 DNA methylation Effects 0.000 abstract description 20
- 210000005259 peripheral blood Anatomy 0.000 abstract description 18
- 239000011886 peripheral blood Substances 0.000 abstract description 18
- 238000013399 early diagnosis Methods 0.000 abstract description 5
- 210000003917 human chromosome Anatomy 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 230000008859 change Effects 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 10
- 101000877857 Homo sapiens Protein FAM83A Proteins 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 101150069400 Slc8a1 gene Proteins 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960001570 ademetionine Drugs 0.000 description 2
- 239000000809 air pollutant Substances 0.000 description 2
- 231100001243 air pollutant Toxicity 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 239000002375 environmental carcinogen Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091062167 DNA cytosine Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 231100000003 human carcinogen Toxicity 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a benzo [ a ] pyrene pollution related specific methylation marker for lung cancer diagnosis, a screening method and application thereof, wherein the diagnosis marker is selected from at least one methylation site on human chromosome 1, chromosome 2 and chromosome 8, and the lung cancer is diagnosed at an early stage by detecting the change of DNA methylation level caused by benzo [ a ] pyrene exposure in peripheral blood. The methylation levels of the three sites have high diagnostic value for the occurrence of the lung cancer, can be conveniently detected by a blood sample, and is favorable for early diagnosis of the lung cancer based on the methylation levels and the cut-off values of the three sites.
Description
Technical Field
The invention relates to the technical field of lung cancer diagnosis and detection, in particular to a benzo [ a ] pyrene pollution-related specific methylation marker for lung cancer diagnosis and a screening method and application thereof.
Background
Lung cancer, as a common malignant tumor with the highest prevalence and mortality in China and even worldwide, has become a major public health problem seriously harming the health and economic development of the whole social population. It is reported that about 180 million people are newly diagnosed as lung cancer every year worldwide, about 160 million people die of lung cancer, and the 5-year survival rate of tumors varies from about 4 to 17% according to the stage and regional difference. The diagnosis of lung cancer is of great significance for therapy.
DNA methylation is one of epigenetic regulation mechanisms, and refers to a chemical modification process in which specific bases on a DNA sequence are catalyzed by DNA methyltransferases (DNMTs) and S-adenosyl methionine (SAM) is used as a methyl donor to transfer methyl to a 5 th carbon atom of DNA cytosine in a covalent bond manner to form 5-methylcytosine (5-mC). The DNA methylation modification can cause the change of chromatin structure, DNA conformation, DNA stability and interaction mode of DNA and protein on the basis of not changing DNA sequence, and regulate gene expression, thereby participating in the process of generating and developing various diseases including cancer.
The association between lung cancer and DNA methylation is mainly reflected in that DNA methylation can promote the occurrence and development of lung cancer by influencing the abnormal expression of related genes. The hypomethylation of the whole genome level can increase the expression level of protooncogenes, thereby promoting the growth, differentiation, invasion, migration and the like of cancer cells to further aggravate the cancer; hypermethylation of local regions such as promoter regions can cause the expression of corresponding genes such as cancer suppressor genes to be silenced, thereby losing the ability to regulate cancer cells. Previous studies found that the major risk factors for lung cancer include smoking, air pollution, heavy metal exposure, occupational exposure, and the like. Recent studies have shown that cigarette smoking, air pollutants, etc. can affect the methylation level of DNA in the body, so that the gene expression is increased or reduced or even silenced, and the epigenetic change related to the environmental factors can have a direct relationship with the cause of cancer. Benzo [ a ] pyrene (Ba P) is a common air pollutant and is a typical representative of carcinogenic Polycyclic Aromatic Hydrocarbon (PAHs) compounds, is listed as a definitive human carcinogen by the international center for cancer research, and can obviously increase the incidence risk of lung cancer. A large number of genome-wide epigenetic studies have shown that environmental contaminants such as benzo [ a ] pyrene can cause abnormal changes in DNA methylation in blood or tissue samples. DNA methylation is involved in the development of lung cancer by changing the expression of the corresponding gene, and early diagnosis of tumors can be achieved by detecting the DNA methylation change caused by benzo [ a ] pyrene exposure in blood or tissues. However, there is currently no study on the alteration of DNA methylation associated with benzo [ a ] pyrene exposure in the diagnosis of lung cancer.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a benzo [ a ] pyrene pollution-related specific methylation marker for lung cancer diagnosis, a screening method and application thereof, wherein the methylation site can be used as a specific methylation site of a lung cancer diagnosis marker related to an environmental carcinogen benzo [ a ] pyrene, the methylation level of the methylation site has higher prediction value on lung cancer occurrence, and the methylation site can be used as a marker for early lung cancer diagnosis.
The technical scheme provided by the invention is as follows: a benzo [ a ] pyrene contamination-associated specific methylation marker for lung cancer diagnosis, the lung cancer diagnosis marker being selected from at least one methylation site on human chromosome 1, chromosome 2 and chromosome 8, wherein the methylation site on human chromosome 1 is cg20460771, the methylation site on chromosome 2 is cg10103850, and the methylation site on chromosome 8 is cg 10424125.
Further, the cg20460771 locus is located on 28521540 of chromosome 1 and on the PTAFR gene; the cg10103850 site is located on chromosome 2 at 40658891, on the SLC8a1 gene; the cg10424125 site is located on 124194624 of chromosome 8 and on FAM83A gene.
Further, the nucleotide sequence around the cg20460771 site is shown as SEQ ID No 1, the nucleotide sequence around the cg10103850 site is shown as SEQ ID No 2, and the nucleotide sequence around the cg10424125 site is shown as SEQ ID No 3.
SEQ ID No 1：
TTCCTGAGTCTGTAAGAGCCACACATACTCCCTACCTCACACTT AGCATGATGACTGGCACGTACCAGGAATTCAGTAAATGAAAA TCACTTTATTTACCCAAGCTCCTGTTGAGTGTCCCA
SEQ ID No 2：
CATACCCTTATGTCCTGGAAAAAGTTAAAAGAGGAACTGGATT ACAGGCTTTCATAGCTTCGGGCTGGCTGAGAGCCACCCCACAT TCGCCTACACTCTCTGGCTCATGTTTGCTGCTGATG
SEQ ID No 3：
TCAGGGATGGCATCTTTCCCCCCCACAGGGAAATTCTTATCTTT GAAACAGCATGGGAATCGAGGCACCCAGGAGGGGAGCAGAG GCAGGCAGGCCTCCTTCAGGCCCATCCTCCAGCTGGG
A screening method of specific methylation sites related to benzo [ a ] pyrene pollution for lung cancer diagnosis comprises the following steps:
(1) peripheral blood of lung cancer patients and healthy controls and lung cancer and tissue samples beside the cancer of the lung cancer patients are obtained and used as samples to be tested of study objects, and plasma and blood cells are separated from the peripheral blood. The level of BPDE-Alb adduct was first measured for each plasma sample as a marker for the level of internal exposure of study individuals to benzo [ a ] pyrene. Lung cancer patients and healthy controls were tested for peripheral blood DNA whole genome methylation levels using Illumina 450K methylation chip (Illumina, usa).
(2) Adopting a minifi software package, carrying out correlation analysis on the peripheral blood DNA methylation level and the plasma BPDE-Alb adduct level through a general linear model, and according to the correlation P value of less than 1.0 multiplied by 10-4In order to have statistical significance, DNA methylation sites which are obviously related to the plasma BPDE-Alb adduct level are screened;
(3) and (3) detecting the methylation level of the tissue DNA whole genome of the lung cancer and the tissues beside the lung cancer of the lung cancer patient obtained in the step (1) by using an Illumina 450K methylation chip (Illumina corporation, USA). By rank-sum test, the methylation sites with significant difference in the DNA of the lung cancer and the tissue beside the cancer are screened out according to the fact that the P value is less than 0.05;
(4) comparing the methylation sites of the intersection of the methylation sites screened in the step (2) and the methylation sites screened in the step (3) as candidate sites;
(5) and (3) analyzing the correlation between the methylation level of the candidate sites obtained in the step (4) in peripheral blood DNA and the occurrence risk of the lung cancer in lung cancer and control populations by using a multivariate logistic regression model, and further screening out the methylation sites related to the lung cancer according to a test standard that the correlation P value of multiple correction of a Bonferroni method is less than 0.05. And evaluating the diagnosis value of the methylation level of the sites on the occurrence of the lung cancer by drawing a ROC curve.
A benzo [ a ] pyrene pollution-related specific methylation detection primer for lung cancer diagnosis comprises at least one of a primer pair for detecting methylation sites on a PTAFR gene, an SLC8A1 gene and a FAM83A gene, wherein the sequences of the primer pair of the PTAFR gene are shown as SEQ ID No 4 and SEQ ID No 5; the primer pair sequence of the SLC8A1 gene is shown as SEQ ID No. 6 and SEQ ID No. 7; the primer pair sequences of the FAM83A gene are shown as SEQ ID No. 8 and SEQ ID No. 9.
SEQ ID No 4：AGGAAAGTAAATTGGGTTATGG
SEQ ID No 5：AAAAAAAAATTAACCCCTAAACCTAAAAC
SEQ ID No 6：GTTAAAAGAGGAATTGGATTATAGGT
SEQ ID No 7：ACAATTTACAATATAAACCATCAACAAC
SEQ ID No 8：AGGGAAATTTTTATTTTTGAAATAGTATGG
SEQ ID No 9：TACCTCTACTCCCCTCCTAAAT
A benzo [ a ] pyrene pollution-related specific methylation detection kit for lung cancer diagnosis comprises at least one of primer pairs of genes where three DNA methylation sites are located, PCR amplification is carried out on DNA of peripheral blood of a crowd, the methylation levels of the three DNA methylation sites are detected by adopting a pyrosequencing method, and then early diagnosis is carried out on the lung cancer.
The invention provides application of the DNA methylation marker for lung cancer diagnosis in preparation of a diagnostic reagent and/or an auxiliary diagnostic reagent.
The invention provides a method for detecting lung cancer, which is characterized in that three methylation sites of a PTAFR gene cg20460771, an SLC8A1 gene cg10103850 and an FAM83A gene cg10424125 can be used as lung cancer diagnosis markers related to an environmental carcinogen benzo [ a ] pyrene, the methylation levels of the 3 sites have high diagnosis value on the occurrence of lung cancer, and a primer pair for detecting the genes of the methylation sites is designed.
Drawings
FIG. 1 is a Manhattan plot of a whole genome correlation assay of peripheral blood DNA methylation with plasma BPDE-Alb adduct levels;
FIG. 2 shows the methylation levels of the three sites cg20460771, cg10103850 and cg10424125 in the peripheral blood DNA of lung cancer patients and healthy control groups;
FIG. 3 is a diagram of ROC curve evaluation of methylation levels of cg20460771, cg10103850 and cg10424125 sites in peripheral blood DNA for predicting value of lung cancer occurrence.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
A benzo [ a ] pyrene contamination-associated specific methylation marker for lung cancer diagnosis, the lung cancer diagnosis marker being selected from at least one methylation site on human chromosome 1, chromosome 2 and chromosome 8, wherein the methylation site on human chromosome 1 is cg20460771, the methylation site on chromosome 2 is cg10103850, and the methylation site on chromosome 8 is cg 10424125.
Further, the cg20460771 locus is located on 28521540 of chromosome 1 and on the PTAFR gene; the cg10103850 site is located on chromosome 2 at 40658891, on the SLC8a1 gene; the cg10424125 site is located on 124194624 of chromosome 8 and on FAM83A gene.
Further, the nucleotide sequence around the cg20460771 site is shown as SEQ ID No 1, the nucleotide sequence around the cg10103850 site is shown as SEQ ID No 2, and the nucleotide sequence around the cg10424125 site is shown as SEQ ID No 3.
TTCCTGAGTCTGTAAGAGCCACACATACTCCCTACCTCACACTT AGCATGATGACTGGCACGTACCAGGAATTCAGTAAATGAAAA TCACTTTATTTACCCAAGCTCCTGTTGAGTGTCCCA
CATACCCTTATGTCCTGGAAAAAGTTAAAAGAGGAACTGGATT ACAGGCTTTCATAGCTTCGGGCTGGCTGAGAGCCACCCCACAT TCGCCTACACTCTCTGGCTCATGTTTGCTGCTGATG
TCAGGGATGGCATCTTTCCCCCCCACAGGGAAATTCTTATCTTT GAAACAGCATGGGAATCGAGGCACCCAGGAGGGGAGCAGAG GCAGGCAGGCCTCCTTCAGGCCCATCCTCCAGCTGGG
Example 1
(1) 2ml of peripheral blood was collected from 109 lung cancer patients and 109 healthy controls, and plasma and blood cells were separated. The BPDE-Alb adduct level was measured for each plasma sample as a marker for the level of internal exposure of study individuals to benzo [ a ] pyrene. Lung cancer patients and healthy controls were tested for peripheral blood DNA whole genome methylation levels using Illumina 450K methylation chip (Illumina, usa).
(2) Correlation analysis was performed on peripheral blood DNA methylation levels and plasma BPDE-Alb adduct levels using the minifi software package by a general linear model, and fig. 1 is a manhattan plot of the correlation of plasma BPDE-Alb adduct levels with peripheral blood whole genome DNA methylation levels. P value less than 1.0 x 10 according to relevance-4To be statistically significant, DNA methylation sites were screened for association with plasma BPDE-Alb adduct levels.
(2) 50mg of lung cancer and tissues beside the lung cancer obtained in the surgical operation of 109 cases of lung cancer patients in the step (1) are respectively taken, DNA samples are extracted, and the DNA whole genome methylation level of the lung cancer and tissues beside the lung cancer is detected by adopting an Illumina 450K methylation chip (Illumina company in the united states). Screening methylation sites with difference in lung cancer and tissues beside the lung cancer by rank sum test according to the fact that the P value is less than 0.05 and the methylation sites have statistically significant difference;
(3) and (3) comparing the methylation sites at the intersection of the methylation sites screened in the step (1) and the methylation sites screened in the step (2) to obtain candidate sites. Information on candidate methylation sites is shown in Table 1.
TABLE 110 methylation sites that differ significantly in methylation levels in DNA from lung cancer and paracancerous tissues and are associated with plasma BPDE-Alb adducts
(4) And (3) further analyzing the correlation between the methylation level of the candidate methylation sites in the peripheral blood DNA and the risk of the occurrence of the lung cancer in lung cancer patients and control populations by using a multivariate logistic regression model, and further screening three methylation sites cg20460771, cg10103850 and cg10424125 which are significantly related to the occurrence of the lung cancer according to a test standard that the correlation P value of multiple correction of a Bonferroni method is less than 0.05. Wherein, the high-level BPDE-Alb adduct can obviously increase the methylation level of the cg20460771 site, and the methylation level of the site can further increase the onset risk of lung cancer; while high levels of BPDE-Alb adduct significantly reduce the methylation levels at sites cg10103850 and cg10424125, the reduced methylation levels at these two sites may further increase the risk of lung cancer. The difference of methylation level of peripheral blood DNA of the lung cancer patients and the healthy control group at the three sites of cg20460771, cg10103850 and cg10424125 is shown in figure 2;
(5) further, the methylation levels of these three sites were evaluated by plotting ROC curves for the diagnostic value of lung cancer development, and the specific results are shown in fig. 3. The result shows that the methylation level of the cg20460771 site has the diagnostic value of 88.9 percent, the sensitivity of 80.73 percent and the specificity of 87.16 percent for the occurrence of the lung cancer; the diagnostic value of the methylation level of the cg10103850 site is 89.2%, the sensitivity is 87.14%, and the specificity is 78.29%; the diagnostic value of the methylation level of the cg10424125 site was 70.8%, the sensitivity was 68.93%, and the specificity was 75.84%.
(6) Further, according to the results of the ROC curve in (5), the methylation levels of cg20460771, cg10103850 and cg10424125 are respectively set as cutoff values of > 67.3%, < 13.9%, < 14.3% for lung cancer diagnosis, namely, the diagnosis result can be determined as positive when the criteria are met. The three indexes are respectively subjected to combined diagnostic analysis, and the detection sensitivity can reach 94.5 percent when the methylation levels of cg20460771 and cg10103850 are detected simultaneously and one index of the two indexes is positive, namely the lung cancer is judged to be positive for diagnosis; when the methylation levels of cg20460771 and cg10424125 are detected simultaneously, if the methylation levels are both positive indexes, the lung cancer is judged to be positive, and the detection specificity can reach 91.74%. Therefore, the methylation levels of cg20460771, cg10103850 and cg10424125 are lung cancer specific diagnostic markers with great potential, can be conveniently detected by peripheral blood samples, and are helpful for early diagnosis of lung cancer based on the methylation levels of the three sites and cut-off values thereof.
A detection primer for benzo [ a ] pyrene pollution-related specific methylation for lung cancer diagnosis comprises at least one of a primer pair for detecting methylation sites on a PTAFR gene, an SLC8A1 gene and a FAM83A gene, wherein the sequences of the primer pair of the PTAFR gene are shown as SEQ ID No 4 and SEQ ID No 5; the primer pair sequence of the SLC8A1 gene is shown as SEQ ID No. 6 and SEQ ID No. 7; the primer pair sequences of the FAM83A gene are shown as SEQ ID No. 8 and SEQ ID No. 9.
SEQ ID No 4：AGGAAAGTAAATTGGGTTATGG
SEQ ID No 5：AAAAAAAAATTAACCCCTAAACCTAAAAC
SEQ ID No 6：GTTAAAAGAGGAATTGGATTATAGGT
SEQ ID No 7：ACAATTTACAATATAAACCATCAACAAC
SEQ ID No 8：AGGGAAATTTTTATTTTTGAAATAGTATGG
SEQ ID No 9：TACCTCTACTCCCCTCCTAAAT
A specific methylation detection kit related to benzo [ a ] pyrene pollution for lung cancer diagnosis comprises at least one of primer pairs of genes where three DNA methylation sites are located, PCR amplification is carried out on peripheral blood of a crowd, the methylation levels of the three DNA methylation sites are detected by pyrosequencing, and then early diagnosis is carried out on the lung cancer.
The above description is only a detailed description of specific embodiments of the present invention, and should not be taken as limiting the invention, and any modifications, equivalents, improvements, etc. made on the design concept of the present invention should be included in the protection scope of the present invention.
Sequence listing
<110> university of science and technology in Huazhong
<120> benzo [ a ] pyrene pollution related specific methylation marker for lung cancer diagnosis, and screening method and application thereof
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 122
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
ttcctgagtc tgtaagagcc acacatactc cctacctcac acttagcatg atgactggca 60
cgtaccagga attcagtaaa tgaaaatcac tttatttacc caagctcctg ttgagtgtcc 120
ca 122
<210> 2
<211> 122
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
cataccctta tgtcctggaa aaagttaaaa gaggaactgg attacaggct ttcatagctt 60
cgggctggct gagagccacc ccacattcgc ctacactctc tggctcatgt ttgctgctga 120
tg 122
<210> 3
<211> 122
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
tcagggatgg catctttccc ccccacaggg aaattcttat ctttgaaaca gcatgggaat 60
cgaggcaccc aggaggggag cagaggcagg caggcctcct tcaggcccat cctccagctg 120
gg 122
<210> 4
<211> 22
<212> DNA
<213> primer for methylation of PTAFR gene (1)
<400> 4
aggaaagtaa attgggttat gg 22
<210> 5
<211> 29
<212> DNA
<213> primer for methylation of PTAFR gene (2)
<400> 5
aaaaaaaaat taacccctaa acctaaaac 29
<210> 6
<211> 26
<212> DNA
<213> primer for methylation of SLC8A1 gene (1)
<400> 6
gttaaaagag gaattggatt ataggt 26
<210> 7
<211> 28
<212> DNA
<213> primer for methylation of SLC8A1 gene (2)
<400> 7
acaatttaca atataaacca tcaacaac 28
<210> 8
<211> 30
<212> DNA
<213> primer for methylation of FAM83A Gene (1)
<400> 8
agggaaattt ttatttttga aatagtatgg 30
<210> 9
<211> 22
<212> DNA
<213> primer for methylation of FAM83A Gene (2)
<400> 9
tacctctact cccctcctaa at 22
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911361331.7A CN111187838B (en) | 2019-12-26 | 2019-12-26 | A specific methylation marker related to benzo[a]pyrene contamination for lung cancer diagnosis and its screening method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911361331.7A CN111187838B (en) | 2019-12-26 | 2019-12-26 | A specific methylation marker related to benzo[a]pyrene contamination for lung cancer diagnosis and its screening method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111187838A CN111187838A (en) | 2020-05-22 |
| CN111187838B true CN111187838B (en) | 2021-09-24 |
Family
ID=70705840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911361331.7A Active CN111187838B (en) | 2019-12-26 | 2019-12-26 | A specific methylation marker related to benzo[a]pyrene contamination for lung cancer diagnosis and its screening method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111187838B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113265454B (en) * | 2021-04-27 | 2023-07-18 | 广州医科大学 | Genome-wide DNA adduct detection method based on combined dot blot hybridization and chromatin immunoprecipitation sequencing |
| CN114164266A (en) * | 2022-01-13 | 2022-03-11 | 青岛大学 | An epigenetic marker for detecting benzo[a]pyrene exposure and its application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018009709A1 (en) * | 2016-07-06 | 2018-01-11 | Youhealth Biotech, Limited | Lung cancer methylation markers and uses thereof |
| CN107881234A (en) * | 2017-11-09 | 2018-04-06 | 南京卡迪睿伯生物技术有限公司 | One group of adenocarcinoma of lung related gene label and its application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014193958A2 (en) * | 2013-05-31 | 2014-12-04 | Onconova Therapeutics, Inc. | Methods and compositions for predicting therapeutic efficacy of kinase inhibitors in patients with myelodysplastic syndrome or related disorders |
-
2019
- 2019-12-26 CN CN201911361331.7A patent/CN111187838B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018009709A1 (en) * | 2016-07-06 | 2018-01-11 | Youhealth Biotech, Limited | Lung cancer methylation markers and uses thereof |
| CN107881234A (en) * | 2017-11-09 | 2018-04-06 | 南京卡迪睿伯生物技术有限公司 | One group of adenocarcinoma of lung related gene label and its application |
Non-Patent Citations (3)
| Title |
|---|
| Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study;Cheng-Lan Jiang等;《Oncotarget》;20161125;第8卷(第1期);摘要、第1372页、Supplementary Table S5-S8、第1384-1386页的材料方法 * |
| Genome-Wide Analysis of DNA Methylation and Cigarette Smoking in a Chinese Population;Xiaoyan Zhu等;《Environmental Health Perspectives》;20160731;第124卷(第7期);第966-973页 * |
| HumanMethylation450 v1.2 Manifest file;Illumina;《Illumina》;20130523;第1-2页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111187838A (en) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Verma et al. | Genome-wide DNA methylation profiling identifies differential methylation in uninvolved psoriatic epidermis | |
| EP2891720B1 (en) | Method for screening cancer | |
| CA2620528A1 (en) | Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states | |
| JP6606554B2 (en) | Use of the methylated site of the Y chromosome as a diagnostic marker for prostate cancer | |
| JP2024105502A (en) | DNA methylation markers for non-invasive detection of cancer and their uses - Patents.com | |
| EP2861992A1 (en) | Methods for head and neck cancer prognosis | |
| WO2020034543A1 (en) | Marker for breast cancer diagnosis and screening method therefor | |
| CN111187838B (en) | A specific methylation marker related to benzo[a]pyrene contamination for lung cancer diagnosis and its screening method and use | |
| JP2022522354A (en) | DNA methylation marker for liver cancer recurrence prediction and its use | |
| CN102424840A (en) | Method and kit for diagnosing recurrence risk of bladder cancer patient by using urine | |
| CN110904231A (en) | Reagent for auxiliary diagnosis of liver cancer and application of reagent in preparation of kit | |
| WO2018020042A1 (en) | Rna editing as biomarkers for mood disorders test | |
| CA3085464A1 (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
| US8771947B2 (en) | Cancer risk biomarkers | |
| CN107119144B (en) | Application of the DNA-binding site CTCF_55 of the multifunctional transcriptional regulator CTCF | |
| JP7105460B2 (en) | Methods for detecting adult T-cell leukemia/lymphoma | |
| JP2020533663A (en) | DNA repair profiling and methods for it | |
| CN109813912B (en) | Application of group of serum differential protein combinations in preparation of reagent for detecting autism | |
| CN107151708B (en) | Application of the DNA-binding site CTCF_13 of the multifunctional transcriptional regulator CTCF | |
| WO2009039190A1 (en) | Cancer risk biomarker | |
| CN107227366B (en) | Application of DNA binding site CTCF-113 of multifunctional transcription regulatory factor CTCF | |
| Li et al. | Development and validation of a five-immune gene pair signature in endometrial carcinoma | |
| Wang et al. | Construction and Validation of a Novel Eight-Gene Risk Score to Predict the Malignant Progression and Prognoses in Bladder Cancer Patients | |
| Wang et al. | Eight-gene risk score predicts progression and prognosis in bladder cancer | |
| Patel et al. | Understanding Molecular Diagnosis in Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |